MRTX - Mirati Therapeutics,...

Financial Statements(Q) of Mirati Therapeutics, Inc.(MRTX), Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address

Mirati Therapeutics, Inc.

MRTX

NASDAQ

Inactive Equity

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

58.7 USD

-0.1 (-0.17%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

All Income Statement Balance Sheet Statement Cash Flow Statement Retained Earning Schedule PPE Schedule Intangible and Goodwill Schedule

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.